Cargando…
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
Thirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder")...
Autores principales: | Thatcher, N., Palmer, M. K., Gasiunas, N., Crowther, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1977
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025560/ https://www.ncbi.nlm.nih.gov/pubmed/597473 |
Ejemplares similares
-
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020) -
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
por: Danilov, Alexey V., et al.
Publicado: (2019) -
Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma
por: Wang, Yuhan, et al.
Publicado: (2023) -
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020) -
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)